COMMUNIQUÉS West-GlobeNewswire

Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery
09/01/2026
Company to present Tuesday, January 13 th at 10:00 a.m. PT / 1:00 p.m. ET GAITHERSBURG, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix [...]
Flare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer
09/01/2026
CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other [...]
Peer-reviewed study demonstrates LEON’s FR-JET® modular mixer enables stable high-concentration mRNA-LNPs with enhanced in vivo activity
09/01/2026
PLANEGG, Germany and MUNICH, Jan. 09, 2026 (GLOBE NEWSWIRE) -- A new study published in Pharmaceutics ( https://doi.org/10.3390/pharmaceutics18010050 ) shows that LEON’s FR-JET ® modular mixer addresses key [...]
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
09/01/2026
-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE ® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preliminary net product [...]
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
09/01/2026
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in March 2026; pending [...]
Tecan to present at upcoming Investor Conferences
09/01/2026
Männedorf, Switzerland, January 9, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will attend and present at the following investor conferences in the upcoming week: 44 th Annual J.P. Morgan [...]
Bruder Consulting & Venture Group to become Dark Horse Consulting Regenerative Medicine
09/01/2026
WALNUT CREEK, Calif. and NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, is pleased to announce the [...]
uniQure Announces Type A Meeting Scheduled with FDA
09/01/2026
LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a [...]
Remedy’s Nutrition® Unveils Hair Tissue Mineral Analysis: A Revolutionary Personalized Approach to Nutritional Wellness
09/01/2026
KEY LARGO, Fla., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Remedy's Nutrition® , a pioneering natural health company established in 1972, today announced the launch of its cutting-edge diagnostic service: Hair Tissue Mineral [...]
Sienna Announces Fourth Quarter 2025 Results Release Date and Conference Call
09/01/2026
MARKHAM, Ontario, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) announced that it will report its 2025 fourth quarter results after market close on Thursday, [...]
ACTG Launches IPACE-HIV to Study Frailty Intervention
09/01/2026
CHAPEL HILL, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the IPACE-HIV study (Improving Physical Ability [...]
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
09/01/2026
MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri [...]
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
09/01/2026
SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and [...]
Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update
09/01/2026
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency’s review of Anaphylm NDA application is [...]
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
09/01/2026
DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on recent innovations in [...]
Memo Therapeutics AG Publishes BKPyV Infection Disease Burden Study in the Journal of Patient-Reported Outcomes
09/01/2026
PRESS RELEASE Memo Therapeutics AG Publishes BKPyV Infection Disease Burden Study in the Journal of Patient-Reported Outcomes First conceptual model demonstrating the impact of BK polyomavirus on the health-related [...]
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
09/01/2026
Immunocore announces 2026 strategic priorities at 44 th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US community and global [...]
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
09/01/2026
BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody [...]
Avance Clinical to Showcase New Early Phase Center of Excellence at Biotech Showcase 2026
09/01/2026
ADELAIDE, Australia, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning Australian led, global CRO built exclusively to service the clinical research needs of biotech companies, announced today that [...]

Pages